

Datasheet for ABIN1415350

anti-ITPR3 antibody (AA 21-120) (Cy3)



_	
Over	/۱۵\۸/
OVCIV	/ I C V V

Alternative Name:

Quantity:	100 μL
Target:	ITPR3
Binding Specificity:	AA 21-120
Reactivity:	Mouse
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This ITPR3 antibody is conjugated to Cy3
Application:	Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc))
Product Details	
Immunogen:	KLH conjugated synthetic peptide derived from human ITPR3
Isotype:	IgG
Cross-Reactivity:	Mouse
Predicted Reactivity:	Human,Rat,Dog,Cow,Horse,Chicken,Rabbit
Purification:	Purified by Protein A.
Target Details	
Target:	ITPR3

Itpr3 (ITPR3 Products)

Target Details

Background:	Synonyms: IP3R-III, IP3 receptor isoform 3, 4 antibody 5-trisphosphate receptor, 5-
	trisphosphate receptor type 3, FLJ36205, Inositol 1, Inositol 1,4,5 trisphosphate receptor type 3
	IP3 receptor, IP3R 3, IP3R, IP3R3, ITPR 3, ITPR3, ITPR3_HUMAN, Type 3 inositol 1, Type 3
	inositol 1,4,5 trisphosphate receptor, Type 3 InsP3 receptor.
	Background: Inositol 1,4,5-triphosphate (IP3) functions as a second messenger for a myriad of
	extracellular stimuli including hormones, growth factors and neurotransmitters. Receptor
	tyrosine kinases indirectly increase the intracellular levels of IP3 through the activation of
	phospholipases such as phospholipase C (PLC), which convert phosphatidylinositol-4,5
	bisphosphate into IP3 and diacylglycerol (DAG). The inositol 1,4,5-triphosphate receptor, IP3R,
	acts as an inositol triphosphate (IP3)-gated calcium release channel in a variety of cell types.
	Three IP3 receptor subtypes have been described and are designated IP3R-I, IP3R-II and IP3R-
	III. IP3R-I is the predominant IP3R subtype expressed in neuronal tissues and the central
	nervous system, but is also expressed at high levels in the liver.
Gene ID:	3710
Pathways:	Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling
Pathways:	rc-epsilon Receptor Signaling Fathway, EGFR Signaling Fathway, Neurotrophili Signaling
Pathways:	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein
Pathways:	
Pathways:	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein
Pathways: Application Details	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein
·	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein
Application Details	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling
Application Details	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200
Application Details	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200
Application Details Application Notes:	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200
Application Details Application Notes:	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200
Application Details Application Notes: Restrictions:	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200
Application Details Application Notes: Restrictions: Handling	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 For Research Use only
Application Details Application Notes: Restrictions: Handling Format:	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 For Research Use only Liquid
Application Details Application Notes: Restrictions: Handling Format: Concentration:	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 For Research Use only Liquid 1 μg/μL
Application Details Application Notes: Restrictions: Handling Format: Concentration:	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 For Research Use only Liquid 1 μg/μL Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and
Application Details Application Notes: Restrictions: Handling Format: Concentration: Buffer:	Pathway, Thyroid Hormone Synthesis, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, BCR Signaling IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 For Research Use only Liquid 1 µg/µL Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Handling

Storage:	-20 °C
Storage Comment:	Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Expiry Date:	12 months